Ignite Creation Date:
2025-12-25 @ 4:52 AM
Ignite Modification Date:
2026-03-04 @ 12:44 AM
Study NCT ID:
NCT05311618
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-01
First Post:
2022-03-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Sponsor:
NGM Biopharmaceuticals, Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
| None | Breast Cancer | View |
| None | Gastric Cancer | View |
| None | Non Small Cell Lung Cancer | View |
| None | Cervical Cancer | View |
| None | Endocervical Cancer | View |
| None | Squamous Cell Carcinoma of Head and Neck | View |
| None | Bladder Urothelial Cancer | View |
| None | Colorectal Cancer | View |
| None | Esophageal Cancer | View |
| None | Ovarian Cancer | View |
| None | Renal Cell Carcinoma | View |
| None | Prostate Cancer | View |
| None | Melanoma | View |
| None | Mesothelioma | View |
| None | Cholangiocarcinoma | View |
Keywords: